A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of MW189 in Patients with Acute, Non-Traumatic, Intracerebral Hemorrhage

Date Added
March 14th, 2022
PRO Number
Pro00118682
Researcher
Charles Andrews

List of Studies


Keywords
Stroke
Summary

The purpose of this study is to learn more about the effects of the study drug called MW189 in people who have bleeding in the brain, including intracerebral hemorrhage or ICH. Some participants in this study will take MW189 and some patients will take placebo (an inactive material that does not contain any active drug).

Participation lasts about 6 months and include approximately 7 study visits to the study center and at least 1 phone call. Participants will have tests, exams and procedures during the study that include blood and urine testing, electrocardiogram (ECG), questionnaires, Magnetic Resonance Imagining (MRI) and Computerized Tomography (CT) scans. Biospecimens will also be collected.

Institution
MUSC
Recruitment Contact
Todd LeMatty
843-792-8538
lematty@musc.edu



-- OR --